Skip to main content
. 2024 Feb 22;10(1):e003855. doi: 10.1136/rmdopen-2023-003855

Figure 1.

Figure 1

Patient disposition. *Patients who withdrew from the study treatment or deviated from assigned randomised treatment but returned for all scheduled visits up to and including week 52. †Two patients classified as ongoing as they did not have a visit for week 52 but no formal discontinuation reason was reported. BKZ, bimekizumab; OLE, open-label extension; Q4W, every 4 weeks.